Dexcom is facing scrutiny and class-action lawsuits over alleged safety and accuracy issues with its G7 monitor.

Oct 30 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab topped Wall Street estimates for third-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring ...

Shares have lagged the market this year, partly due to some public image and regulatory issues. DexCom's stock could drop even more if results falls short of revenue expectations. Whatever happens on ...

Oct 31 (Reuters) - Dexcom (DXCM.O), opens new tab shares tumbled 12.8% on Friday after executives signaled that the medical device maker's 2026 growth forecast could fall short of Wall Street ...

DexCom receives a BUY rating due to strong growth, expanding margins, and the launch of Stelo, the first OTC CGM for non-insulin users. DXCM raised its 2025 outlook, targeting $4.6B+ in revenue, 62% ...

Earlier this month, DexCom reported stronger-than-expected second quarter revenues but issued the weakest full-year outlook among patient monitoring peers, following a sector-wide selloff triggered by ...

If you’re trying to figure out whether now’s the time to buy, hold, or even sell DexCom stock, you’re not alone. After all, its share price has been a bit of a roller coaster lately. Over the last ...

TORONTO -- Blue Jays manager John Schneider said injured designated hitter George Springer was on track to play in Game 6 of the World Series on Friday. Springer, who strained muscles on his right ...

Nasha is a Managing Editor for CNET, overseeing our sleep and wellness verticals. She is a nutrition, mental health, fitness and sleep science enthusiast. Her passion for mindful and holistic ...